Putnam’s Centers of Excellence allow us to dig deep, challenge convention, and take you further with strategies underpinned by technical expertise in cutting-edge topics.
A strategic thought partner for your AI journey
Explore our latest insights and perspectives in these life science resources, news articles, and events.
Putnam shares key questions to consider in preparation of advancing trials and deals that have been put on hold.
We explore two instances where our consulting teams used AssetNav to help clients prioritize promising BD&L opportunities in oncology.
Putnam experts share observations on recent global trends in the rare disease space and recommend strategies to maximize opportunities.
In recent years, we have observed increasing clinical development activity in autoimmune diseases, including for Myasthenia Gravis (MG).
Our experts take a deep dive into the growing oncology market uncovering the top drivers and activities of revenue growth.
We’re sharing some spotlights to help support our clients and partners navigate ASH 2023.
ADCs continued to be a spotlight at ESMO 2023. The team shares its key value drivers and associated limitations.
The client sought Putnam’s guidance on a go/no-go development decision for a first-generation targeted therapy in Phase 1 clinical development.
A clinical-stage biopharmaceutical company sought Putnam’s guidance to prioritize asset-level strategies through a holistic review of options.
The pre-clinical and early clinical data presented at AACR should be of keen interest to oncology drug developers.
We developed a forward-looking early development program evaluation tool that identifies key inflection points for early oncology portfolio.
Our cell and gene therapy experts offer a deep analysis on the current opportunities and challenges of cell therapies for solid tumors.
Looking to get in touch with an expert or team member?
Tell us how we can help.
